Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 20/20 | 0.80 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982229 | 1.00 | OXTR (0.80) | OXTRAVPR2 | |
| SCHEMBL1598441 | 1.00 | OXTR (0.80) | OXTRAVPR2 | |
| SCHEMBL5420992 | 0.93 | OXTR (0.80) | OXTRAVPR2 | |
| SCHEMBL12727702 | 0.92 | OXTR (0.68) | OXTRAVPR2 | |
| SCHEMBL1598563 | 0.89 | OXTR (1.00) | OXTRAVPR2 | |
| SCHEMBL9975177 | 0.87 | OXTR (0.81) | OXTRAVPR2 | |
| SCHEMBL1598224 | 0.87 | OXTR (0.81) | OXTRAVPR2 | |
| SCHEMBL5483388 | 0.87 | OXTR (0.81) | OXTRAVPR2 | |
| SCHEMBL9973568 | 0.87 | OXTR (0.83) | OXTRAVPR2 | |
| SCHEMBL8277533 | 0.87 | OXTR (0.83) | OXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408851-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160030442-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20150157640-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-06-11 | — | — | US | disclosed |
| US-8815856-B2 | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione | GLAXO GROUP LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-20140235639-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-08-21 | — | — | US | disclosed |
| US-20140200218-A1 | NOVEL CRYSTALLINE FORMS OF (3R, 6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-[(1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)-2-(4-MORPHOLINYL)-2-OXOETHYL]-6-[(1S)-1-METHYLPROPYL]-2,5-PIPERAZINEDIONE | GLAXO GROUP LIMITED (GB) | 2014-07-17 | — | — | US | disclosed |
| US-20140200218-A1 | NOVEL CRYSTALLINE FORMS OF (3R, 6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-[(1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)-2-(4-MORPHOLINYL)-2-OXOETHYL]-6-[(1S)-1-METHYLPROPYL]-2,5-PIPERAZINEDIONE | GLAXO GROUP LIMITED (GB) | 2014-07-17 | — | — | US | disclosed |
| US-8742099-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8716286-B2 | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione | GLAXO GROUP LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-20130253188-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130109690-A1 | NOVEL CRYSTALLINE FORMS OF (3R, 6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-[(1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)-2-(4-MORPHOLINYL)-2-OXOETHYL]-6-[(1S)-1-METHYLPROPYL]-2,5-PIPERAZINEDIONE | GLAXO GROUP LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-8202864-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-20110152262-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | US | disclosed |
| US-7919492-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-20100305127-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20090247541-A1 | Novel compounds | BORTHWICK ALAN DAVID | 2009-10-01 | — | — | US | disclosed |
| US-7550462-B2 | Piperazinediones as oxytocin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-06-23 | — | — | US | disclosed |
| US-20070254888-A1 | Piperazinediones as Oxytocin Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254888-A1 | Piperazinediones as Oxytocin Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109690-A1 | NOVEL CRYSTALLINE FORMS OF (3R, 6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-[(1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)-2-(4-MORPHOLINYL)-2-OXOETHYL]-6-[(1S)-1-METHYLPROPYL]-2,5-PIPERAZINEDIONE | CYP2S1, CYP2D6, CYP2B6 | OXTR 2948/4885AVPR2 485/4885 |
| US-20140200218-A1 | NOVEL CRYSTALLINE FORMS OF (3R, 6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-[(1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)-2-(4-MORPHOLINYL)-2-OXOETHYL]-6-[(1S)-1-METHYLPROPYL]-2,5-PIPERAZINEDIONE | CYP2S1, CYP2D6, CYP2B6 | OXTR 2723/4885AVPR2 491/4885 |
| US-20090247541-A1 | Novel compounds | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885 |
| US-20140235639-A1 | NOVEL COMPOUNDS | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885 |
| US-20100305127-A1 | NOVEL COMPOUNDS | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885 |
| US-20130253188-A1 | NOVEL COMPOUNDS | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885 |
| US-20150157640-A1 | NOVEL COMPOUNDS | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885 |
| US-20110152262-A1 | NOVEL COMPOUNDS | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885 |
| US-20160030442-A1 | NOVEL COMPOUNDS | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885 |
| US-20070254888-A1 | Piperazinediones as Oxytocin Receptor Antagonists | OXTR, PRLHR, AVPR2 | OXTR 1/4885AVPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.